CONBRIZA

País: Israel

Idioma: inglés

Fuente: Ministry of Health

Ingredientes activos:

BAZEDOXIFENE AS ACETATE 20 MG

Disponible desde:

NEOPHARM LTD

Código ATC:

G03XC02

formulario farmacéutico:

COATED TABLETS

Vía de administración:

PER OS

Fabricado por:

PFIZER IRELAND PHARMACEUTICALS

Grupo terapéutico:

BAZEDOXIFENE

indicaciones terapéuticas:

CONBRIZA is indicated for the treatment of postmenopausal osteoporosis in women at increased risk of fracture. A significant reduction in the incidence of vertebral fractures has been demonstrated; efficacy on hip fractures has not been established. When determining the choice of CONBRIZA or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefit

Fecha de autorización:

2013-04-01